Arcturus Therapeutics Holdings (ARCT) Operating Leases: 2019-2025
Historic Operating Leases for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $21.9 million.
- Arcturus Therapeutics Holdings' Operating Leases fell 15.86% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 15.86%. This contributed to the annual value of $25.0 million for FY2024, which is 3.51% down from last year.
- Arcturus Therapeutics Holdings' Operating Leases amounted to $21.9 million in Q3 2025, which was down 4.66% from $22.9 million recorded in Q2 2025.
- Over the past 5 years, Arcturus Therapeutics Holdings' Operating Leases peaked at $32.2 million during Q2 2022, and registered a low of $4.1 million during Q1 2022.
- Over the past 3 years, Arcturus Therapeutics Holdings' median Operating Leases value was $26.0 million (recorded in 2024), while the average stood at $25.9 million.
- Its Operating Leases has fluctuated over the past 5 years, first dropped by 28.95% in 2022, then soared by 619.42% in 2023.
- Over the past 5 years, Arcturus Therapeutics Holdings' Operating Leases (Quarterly) stood at $4.5 million in 2021, then soared by 571.17% to $30.2 million in 2022, then decreased by 14.26% to $25.9 million in 2023, then fell by 3.51% to $25.0 million in 2024, then fell by 15.86% to $21.9 million in 2025.
- Its Operating Leases was $21.9 million in Q3 2025, compared to $22.9 million in Q2 2025 and $24.0 million in Q1 2025.